There's a lot to like about Commonwealth Bank of Australia (ASX: CBA). It is an incredible business with a dominant market position and a history of delivering strong shareholder returns.
But I think CBA shares are simply too expensive at current levels.
And if I had to choose just one ASX stock to put my money into instead, there's another company I'd much rather own.

Image source: Getty Images
Why I'm avoiding CBA shares
My biggest issue with CBA is its valuation. The banking giant is currently trading on a forward PE ratio of approximately 25x. That's a huge premium for a mature bank with a relatively subdued earnings growth outlook.
Its recent trading update didn't convince me that this valuation is justified.
CBA reported quarterly cash earnings of approximately $2.8 billion, broadly flat on the second-half FY 2026 quarterly average.
With competition for mortgages and deposits remaining strong, alongside higher operating costs and credit losses, I struggle to see where the earnings growth needed to justify its premium will come from.
If CBA shares were 30% to 40% cheaper, I'd be loading up the truck. But at current levels, I'm happy to look elsewhere.
Why I'd buy this ASX stock instead
One ASX share I'd much rather put all my money into is sleep disorder treatment company ResMed Inc. (ASX: RMD).
I'm a big fan of this business and believe it has an excellent opportunity to continue growing its earnings at a strong rate for many years.
ResMed is a global leader in sleep apnoea treatment, supplying devices and masks to patients around the world.
And with estimates suggesting that approximately one billion people worldwide suffer from sleep apnoea, many of whom remain undiagnosed or untreated, there's a huge opportunity to grow its customer base.
This is being supported by increasing awareness of the condition, improved diagnosis rates, and growing recognition of the health consequences of untreated sleep apnoea.
Importantly, each new patient also creates opportunities for recurring revenue as masks and accessories are replaced.
This is already a major contributor to ResMed's growth. In the first quarter of FY 2027, mask and accessories revenue increased 10% in the Americas and 11% internationally.
More positives
Another thing I like is the company's ongoing investment in innovation and its ability to maintain its leading market position.
It invests heavily in R&D to ensure that its technology remains industry-leading.
And while there have been concerns about the impact of GLP-1 weight-loss medications, ResMed's latest patient research suggests these treatments could actually encourage more people to start and continue sleep apnoea therapy.
Pleasingly, revenue growth is translating into even stronger earnings growth.
In its latest quarter, core revenue increased 7%, while adjusted earnings per share jumped 14%. Management also expects further improvements in profitability through its manufacturing and productivity initiatives.
With a huge market opportunity, growing recurring revenue, and opportunities to improve margins, I believe ResMed could deliver excellent returns over the next decade.
And with a PE ratio of 21x, based on current earnings per share, that's the kind of business I'd much rather own than pay a premium for CBA's slower growth.